ClinicalTrials.gov
public full text
Public Domain
Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors
In this study, response to treatment and (progression free and overall) survival will be described and safety events of ivosidenib in combination with nivolumab will be summarized in patients with advanced solid tumors (nonresectable or metastatic) or enhancing gliomas.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- A Randomized Phase II Clinical Trial on the Efficacy of Axitinib as a Monotherapy or in Combination With Lomustine for the Treatment of Patients With Recurrent Glioblastoma#863222
- Niraparib In Recurrent IDH 1/2 Gliomas#835235
- Ivonescimab combined with chemotherapy for the treatment of metastatic cervical cancer: A case report and literature review#125743
- Nivolumab in Patients With Recurrent Malignant Mesothelioma#467598
- Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma#994305
Record · ID 1466215
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive